期刊文献+

RECURRENCE RISK FACTORS IN PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF BLADDER 被引量:1

RECURRENCE RISK FACTORS IN PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF BLADDER
下载PDF
导出
摘要 Objective: To study recurrence factors and set up a model to evaluate the prognosis of patients with bladder cancer. Methods: An analysis on recurrence-related factors was made by Cox's proportional hazards model analysis and logistic multiple linear regression model analysis in 212 patients with transitional cell carcinoma treated surgically from 1995-2001. These factors included clinical and pathologic figures. Results: The most important factor is metastasis to the regional lymph nodes, the Hazards ratio is 6.6 (P=0.0004), followed by multiple tumors (Hr=2.255, P〈0.0001), tumor in trigone and bladder neck (Hr=2.053, P〈0.0001), stage (Hr=2.057, P〈0.0001), grade (Hr=1.569, P=0.0081), intravesical chemotherapeutic instillations (Hr-0.559, P=0.0011) and hematuria (Hr=0.762, P=0.0076). A predicting equation was established, and the predicting values were calculated according to the individual features of patients. The predicting and actual values were compared, and the sensitivity, specificity and overall concordance were 83.5%, 67.6% and 80.1% respectively. Conelusion:The evaluation of prognosis could be made quite accurately based on these factors. Objective: To study recurrence factors and set up a model to evaluate the prognosis of patients with bladder cancer. Methods: An analysis on recurrence-related factors was made by Cox's proportional hazards model analysis and logistic multiple linear regression model analysis in 212 patients with transitional cell carcinoma treated surgically from 1995-2001. These factors included clinical and pathologic figures. Results: The most important factor is metastasis to the regional lymph nodes, the Hazards ratio is 6.6 (P=0.0004), followed by multiple tumors (Hr=2.255, P〈0.0001), tumor in trigone and bladder neck (Hr=2.053, P〈0.0001), stage (Hr=2.057, P〈0.0001), grade (Hr=1.569, P=0.0081), intravesical chemotherapeutic instillations (Hr-0.559, P=0.0011) and hematuria (Hr=0.762, P=0.0076). A predicting equation was established, and the predicting values were calculated according to the individual features of patients. The predicting and actual values were compared, and the sensitivity, specificity and overall concordance were 83.5%, 67.6% and 80.1% respectively. Conelusion:The evaluation of prognosis could be made quite accurately based on these factors.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2005年第4期278-282,共5页 中国癌症研究(英文版)
基金 This work was supported by a grant from the National Natural Science Foundation of China (No. 30271301).
关键词 Bladder cancer Transitional cell carcinoma RECURRENCE Bladder cancer Transitional cell carcinoma Recurrence
  • 相关文献

参考文献17

  • 1Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer[J]. Cancer Control 2000, 7:335-9.
  • 2Shah SC, Kusiak A, O'donnell MA, et al. Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment[J]. Comput Boil Med 2005, 21 (Epub ahead of print).
  • 3Aveyard P Adab P, Cheng KK, et al. Does smoking status influence the prognosis of bladder cancer? A systematic review[J]. BJU Int 2002, 90:228-39.
  • 4Wang P, Liu YL, Gong DX, et al. The evaluation of recurrence risk of bladder transitional cell carcinoma[J].Chin J Urol 2001, 22:40-2.
  • 5Erchert M, Stenzl A, Falk M, et al. Incidence of urethral tumor involvement in 910 men with bladder cancer[J].World J Urol 1996, 14:3-8.
  • 6Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer[J]. J Urol 2005, 174:14-20.
  • 7Matsui Y, Nishiyama H, Watanabe J, et al. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan[J]. Int J Clin Oncol 2005, 10:133-8.
  • 8Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel,carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium[J]. Cancer 2005, 103:2298-303.
  • 9Cheng CW, Chan SF, Chan LW, et al. Twelve-year follow up of a randomized prospective trial comparing bacillus calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer[J]. Int J Urol 2005, 12:449-55.
  • 10Mugiya S, Nagata M, Takayama T, et al. Intravesical Bacillus Calmette-Guerin (BCG: Yokyo 172 strain)instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG[J].Hinyokika Kiyo 2004, 50:469-73.

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部